AnaptysBio, Inc. (NASDAQ:ANAB) Receives $54.64 Average PT from Brokerages

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been assigned an average recommendation of “Moderate Buy” from the twelve analysts that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $54.64.

A number of equities analysts recently issued reports on ANAB shares. Truist Financial boosted their price objective on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. Wedbush reiterated an “outperform” rating and issued a $42.00 price target on shares of AnaptysBio in a report on Thursday, September 26th. JPMorgan Chase & Co. boosted their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of AnaptysBio in a research note on Wednesday, August 14th. Finally, Guggenheim raised their target price on AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, October 21st.

AnaptysBio Trading Down 0.6 %

NASDAQ ANAB opened at $32.03 on Wednesday. The stock has a market cap of $875.03 million, a price-to-earnings ratio of -5.22 and a beta of -0.29. AnaptysBio has a 12 month low of $13.36 and a 12 month high of $41.31. The company’s 50 day moving average is $35.45 and its two-hundred day moving average is $29.78.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The firm had revenue of $10.97 million for the quarter, compared to analysts’ expectations of $25.85 million. Sell-side analysts forecast that AnaptysBio will post -6.84 EPS for the current year.

Insider Buying and Selling at AnaptysBio

In other news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the transaction, the insider now directly owns 15,398 shares in the company, valued at approximately $595,440.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now directly owns 15,398 shares in the company, valued at approximately $595,440.66. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the transaction, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,440 shares of company stock worth $892,936 over the last quarter. 33.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

Hedge funds have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC purchased a new position in shares of AnaptysBio during the first quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in AnaptysBio during the 1st quarter valued at about $265,000. Susquehanna Fundamental Investments LLC acquired a new position in AnaptysBio in the 1st quarter valued at about $1,221,000. Acadian Asset Management LLC purchased a new stake in AnaptysBio during the first quarter worth about $420,000. Finally, Platinum Investment Management Ltd. purchased a new stake in AnaptysBio during the first quarter worth about $1,490,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.